Literature DB >> 25425223

Influence of Body Mass Index on the Activated Clotting Time Under Weight-Based Heparin Dose.

Xia Hong1, Pei-Ren Shan1, Wei-Jian Huang1, Qian-Li Zhu1, Fang-Yi Xiao1, Sheng Li1, Hao Zhou1.   

Abstract

BACKGROUND: Activated clotting time (ACT) has been successfully applied during percutaneous coronary intervention (PCI) to monitor the extent of thrombin inhibition and anti-coagulation from unfractionated heparin (UFH) aiming to reduce the incidence of thrombotic adverse events and hemorrhagic complications. And this investigation was to explore the influence of body mass index (BMI) on ACT in patients received weight-based dose of UFH during PCI treatment.
METHODS: 78 male patients undergoing coronary angiography or PCI treatment with a mean age of 63.86 ± 6.89 years were enrolled in this study. The patients were statistically divided into four quartiles according to their BMI. The ACT values were recorded as ACT0 , ACT5 , ACT10 , ACT30 and ACT60 , respectively. Taking the preoperative ACT0 as reference, and the differences of the other ACT values with ACT0 was indicated as ΔACTs. ACT values peaked at 5 min in 33.33% of the patients, 10 min in 51.33% of the patients and 30 min in 15.34% of the patients, respectively.
RESULTS: In addition, significant differences were found in overall maximum post-UFH ACT values among all BMI quartiles. UFH doses per blood volume were significantly different among the BMI quartiles, showing a positive association with BMI quartiles; further evidence revealed that the areas under the ΔACT-time curves increased gradually from quartile I to quartile IV. The proportions of ACT60 > 250 s and ACT60 > 300 s were found to be positively correlated with the increased BMI at 60 min after heparin loading.
CONCLUSIONS: The results of our study have shown that a standardized dosing nomogram that uses the actual body weight to calculate the heparin doses may result in UFH overdose for patients with higher BMI compared to patients with lower BMI. © 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  activated blotting time; body mass index; unfractionated heparin

Mesh:

Substances:

Year:  2014        PMID: 25425223      PMCID: PMC6807074          DOI: 10.1002/jcla.21823

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  37 in total

1.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

Authors:  Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting
Journal:  J Am Coll Cardiol       Date:  2011-11-07       Impact factor: 24.094

2.  Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).

Authors:  Michael Koutouzis; Bo Lagerqvist; Stefan James; Elmir Omerovic; Göran Matejka; Lars Grip; Per Albertsson
Journal:  Heart       Date:  2011-04-12       Impact factor: 5.994

3.  The effect of sex, age and race on estimating percentage body fat from body mass index: The Heritage Family Study.

Authors:  A S Jackson; P R Stanforth; J Gagnon; T Rankinen; A S Leon; D C Rao; J S Skinner; C Bouchard; J H Wilmore
Journal:  Int J Obes Relat Metab Disord       Date:  2002-06

4.  Effects of glycosylation on heparin binding and antithrombin activation by heparin.

Authors:  Laercio Pol-Fachin; Camila Franco Becker; Jorge Almeida Guimarães; Hugo Verli
Journal:  Proteins       Date:  2011-07-18

Review 5.  Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients.

Authors:  Donald L Yee; Sarah H O'Brien; Guy Young
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

Review 6.  Safety profile of different low-molecular weight heparins used at therapeutic dose.

Authors:  Isabelle Gouin-Thibault; Eric Pautas; Virginie Siguret
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

7.  Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux.

Authors:  Philippe Gabriel Steg; Shamir Mehta; Sanjit Jolly; Denis Xavier; Hans-Juergen Rupprecht; Jose Luis Lopez-Sendon; Susan Chrolavicius; Sunil V Rao; Christopher B Granger; Janice Pogue; Shiona Laing; Salim Yusuf
Journal:  Am Heart J       Date:  2010-12       Impact factor: 4.749

8.  Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI.

Authors:  W J Kikkert; S H van Nes; K V V Lieve; G D Dangas; J van Straalen; M Vis; J Baan; K T Koch; R J de Winter; J J Piek; J G P Tijssen; J P Henriques
Journal:  Thromb Haemost       Date:  2013-02-28       Impact factor: 5.249

9.  The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial.

Authors:  R A Raschke; B M Reilly; J R Guidry; J R Fontana; S Srinivas
Journal:  Ann Intern Med       Date:  1993-11-01       Impact factor: 25.391

Review 10.  Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer.

Authors:  Jeanine M Walenga; Gary H Lyman
Journal:  Crit Rev Oncol Hematol       Date:  2013-07-12       Impact factor: 6.312

View more
  1 in total

1.  Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients.

Authors:  Anne-Céline Martin; Sarah Lessire; Isabelle Leblanc; Anne-Sophie Dincq; Ivan Philip; Isabelle Gouin-Thibault; Anne Godier
Journal:  Clin Cardiol       Date:  2018-05-10       Impact factor: 2.882

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.